Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

iwMyeloma 2017 | Why one size should not fit all for multiple myeloma

Gareth Morgan • 18 Oct 2017
iwMyeloma 2017
Multiple Myeloma

Within multiple myeloma (MM), there are biologically different diseases that are distinctly characterized. In this video, Gareth Morgan, MD, FRCP, FRCPath, PhD from the UAMS Myeloma Institute, Little Rock, AR, speaking from the Myeloma 2017 meeting in Edinburgh, UK, talks passionately about this hot topic. He highlights the need for risk-stratified treatment in MM.

More from Gareth Morgan

Integrating molecular diagnostics in smoldering myeloma to predict disease progression
1:37
Integrating molecular diagnostics in smoldering myeloma to predict disease progression
Gareth Morgan • 7 Dec 2025
Molecular classification of Waldenström’s macroglobulinemia: the identification of two subtypes
2:03
Molecular classification of Waldenström’s macroglobulinemia: the identification of two subtypes
Gareth Morgan • 7 Dec 2025
Circulating malignant plasma cell biology in HRMM: detecting PR cells at the single cell level
7:13
Circulating malignant plasma cell biology in HRMM: detecting PR cells at the single cell level
Gareth Morgan • 23 Oct 2025
Considering frailty in myeloma treatment decisions: advice for clinicians
2:17
Considering frailty in myeloma treatment decisions: advice for clinicians
Gareth Morgan • 18 Sep 2025

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Gareth Morgan • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Gareth Morgan • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Gareth Morgan • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Gareth Morgan • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals